AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL

Core Insights - Amgen's Repatha (evolocumab) has shown significant reductions in major adverse cardiovascular events (MACE) in high-risk adults without prior heart attacks or strokes, marking it as the first PCSK9 inhibitor to achieve this [1][2][6] Clinical Trial Results - The Phase 3 VESALIUS-CV trial involved over 12,000 patients with atherosclerosis or diabetes, demonstrating a 25% relative reduction in the risk of coronary heart disease death, heart attack, or ischemic stroke (3-P MACE) and a 19% reduction in a broader composite including ischemia-driven revascularization (4-P MACE) [1][6] - Repatha reduced the risk of heart attack by 36% and achieved a median LDL-C level of 45 mg/dL compared to 109 mg/dL in the placebo group [1][6] Importance of LDL-C Management - The results emphasize the critical need for intensive LDL-C lowering to reduce cardiovascular risk, particularly in patients with diabetes who are often undertreated [2][3] - The American Diabetes Association highlights the importance of managing LDL-C in primary care settings to address cardiovascular disease, which is a leading cause of mortality among diabetic patients [3] Market and Accessibility - Repatha has been used by over 6.7 million patients globally since its approval in 2015, with recent FDA approvals expanding its use to adults at increased risk for major adverse cardiovascular events due to uncontrolled LDL-C [5][6] - AmgenNow, a direct-to-patient program, offers Repatha at a monthly price of $239, significantly lower than the previous U.S. list price [5] Commitment to Cardiovascular Innovation - Amgen is dedicated to advancing cardiovascular care through innovative treatments targeting various risk factors associated with cardiovascular disease [6][10] - The company has a robust pipeline of investigational treatments aimed at improving patient outcomes in cardiovascular health [6][10]